Insider Trading March 16, 2026

Zimmer Biomet SVP Lori Winkler Sells $250,849 in Company Stock

Transaction follows robust fourth-quarter results and coincides with cautious 2026 outlook and new analyst coverage

By Caleb Monroe ZBH
Zimmer Biomet SVP Lori Winkler Sells $250,849 in Company Stock
ZBH

Lori Winkler, senior vice president and chief human resources officer at Zimmer Biomet Holdings, sold 2,650 shares on March 12, 2026, generating proceeds of $250,849. The executive retains 10,224 shares after the sale. The transaction arrives amid a fourth-quarter earnings beat, a guarded outlook for 2026, and fresh coverage from William Blair assigning a Market Perform rating.

Key Points

  • Lori Winkler, Zimmer Biomet SVP and CHRO, sold 2,650 shares on March 12, 2026, at $94.66 per share for total proceeds of $250,849.
  • Winkler retains direct ownership of 10,224 shares following the sale; the transaction was disclosed in company filings.
  • Zimmer Biomet reported a fourth-quarter earnings beat, issued a cautious outlook for 2026, and was initiated at Market Perform by William Blair, which cited efforts to expand the product lineup and pipeline through divestitures and tuck-in acquisitions - impacting the healthcare and medical devices sectors.

Lori Winkler, who serves as senior vice president and chief human resources officer at Zimmer Biomet Holdings, Inc. (NYSE:ZBH), completed a sale of company stock on March 12, 2026. According to the filing, Winkler sold 2,650 shares of common stock at $94.66 per share, producing total gross proceeds of $250,849.

Following this disposition, Winkler is recorded as directly owning 10,224 shares of Zimmer Biomet common stock. The filing does not provide additional context for the sale.


That insider transaction arrives while the company has recently reported results and received renewed analyst attention. Zimmer Biomet posted fourth-quarter earnings that exceeded analyst expectations. Management paired that earnings beat with a cautious outlook for 2026, a stance described as reflective of the company’s strategic considerations for the year ahead.

Separately, William Blair initiated coverage of Zimmer Biomet and assigned a Market Perform rating. In its initiation note, the firm highlighted the company’s multi-year efforts to broaden its product array and deepen its development pipeline, noting that those efforts have included divestitures and tuck-in acquisitions over the past five years. William Blair framed these actions as initiatives intended to accelerate revenue growth and said it appreciated the company’s focus on strengthening its market position.

Taken together, the insider sale, the stronger-than-expected quarterly results, the cautious 2026 outlook and the new analyst coverage give investors several recent data points about Zimmer Biomet’s current performance and management priorities. The filings and analyst commentary cited here provide information on recent transactions and corporate strategy, but do not include guidance beyond the statements referenced above.

All figures and assertions in this report are drawn from the company’s disclosures and the analyst initiation referenced in the filings.

Risks

  • The company’s cautious 2026 outlook introduces uncertainty about near-term revenue and margin trajectories - this affects investors evaluating healthcare and medical device exposure.
  • Zimmer Biomet’s reliance on divestitures and tuck-in acquisitions to expand its product lineup and pipeline carries execution and integration uncertainty that could influence the company’s growth profile in the medical devices sector.
  • Insider selling, such as the transaction by the company’s CHRO, can create short-term market perception uncertainty around executive sentiment, which may influence investor sentiment in healthcare-related equities.

More from Insider Trading

Arq General Counsel Makes Small Insider Purchase as Company Navigates Operational Hurdles Mar 16, 2026 Howard Hughes General Counsel Buys $81,206 in Company Stock Mar 16, 2026 Warner Bros. Discovery Director Sells $962K in Stock as Deal Activity Drives Analyst Moves Mar 16, 2026 Canada Pension Plan Investment Board Disposes $213.85 Million in California Resources Stock Mar 16, 2026 Extra Space Storage CEO executes $1.07M stock sale amid firm earnings beat and analyst reassessment Mar 16, 2026